Buscar
Mostrando ítems 1-10 de 991
COMPARISON OF TWO PROGNOSTIC SCORES FOR PATIENTS WITH PAROTID CARCINOMA
(John Wiley & Sons IncHobokenEUA, 2009)
Application of the pediatric risk of mortality (PRISM) score and determination of mortality risk factors in a tertiary pediatric intensive care unit
(Faculdade de Medicina / USP, 2010)
INTRODUCTION: To establish disease severity at admission can be performed by way of the mortality prognostic. Nowadays the prognostic scores make part of quality control and research. The Pediatric Risk of Mortality is one ...
The prognostic accuracy evaluation of SAPS 3, SOFA and APACHE II scores for mortality prediction in the surgical ICU: an external validation study and decision-making analysis
(Universidade Federal de Minas GeraisBrasilEEF - DEPARTAMENTO DE FISIOTERAPIAUFMG, 2019-01)
Prognostic relevance of cytogenetic systems in myelodysplastic syndromes
(Taylor & Francis Ltd, 2012-08)
We have read with great interest the recent article by Qu et al . reporting the impacts of diff erent cytogenetic categories in the Revised International Prognostic Scoring System (IPSS-R) on the prognosis of primary ...
SCORE PROGNOSIS FOR THE INFERTILE COUPLE BASED ON HISTORICAL FACTORS AND SPERM ANALYSIS
(Elsevier Sci Ireland LtdClareIrlanda, 1994)
Score BISAP validation as a prognostic system in acute pancreatitis. Validación del score de BISAP como sistema pronóstico en pancreatitis aguda
(2011-07)
BACKGROUND: The BISAP score is a simple system, which englobes clinical features (laboratory and imagenology tests) allowing to predict the mortality in acute pancreatitis within the first 24 hours of hospitalization. ...
PaP Score (palliative prognostic score) en pacientes con cáncer avanzado en el servicio de medicina paliativa y tratamiento del dolor del Instituto Nacional de Enfermedades Neoplásicas
(Universidad Peruana Cayetano HerediaPE, 2015)
NO TIENE RESUMEN
Influence of Acute Myeloid Leukemia Progression on the Prognosis of 831 Patients With Myelodysplastic Syndromes From the Argentine Database
(Elsevier Inc, 2017-11)
In our retrospective review of 831 patients with myelodysplastic syndromes, 158 developed progression with a very poor outcome (median survival after evolution, 3.5 months). The survival of patients with adverse karyotypes ...